JGJudit González-Gallego

Judit González-Gallego

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judit González-Gallego has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Erturk

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Barbara Lindner

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Carolina Cardoso Gonçalves

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Dennis Crusius

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Dominik Paquet

    Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany

    1 shared publication
  • Georg Kislinger

    German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions

    by Judit González-Gallego, Katalin Todorov-Völgyi, Stephan A. Müller, Sophie Antesberger, Mihail Ivilinov Todorov, Rainer Malik, Rita Grimalt-Mirada, Carolina Cardoso Gonçalves, Martina Schifferer, Georg Kislinger, et al.

    Blood–brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.